Emerging Therapies Foretell New Era for Cutaneous Disorders

Analogous to the early 2000s when treatment options for psoriasis jumped, the same may be true now for treating cutaneous autoimmune disorders.

Related Keywords

United States ,France ,Ohio ,Cleveland ,American ,Anthony Fernandez ,Astrazeneca ,Drug Administration ,American Academy Of Dermatology ,Pfizer ,Cleveland Clinic ,Cutaneous Lupus Erythematosus Disease Area ,Severity Index ,Cutaneous Dermatomyositis Disease Area ,New England Journal ,American Academy ,Systemic Lupus Erythematosus Sle Erythaematosus ,Dermatomyositis ,Lupus ,Cutaneous Lupus Erythematosus Erythaematosus ,Biologic Therapy ,Iologics ,Psoriasis ,Interferon Beta ,Fn Beta ,Monoclonal Antibody ,Etuximab ,Ituximab ,Multiple Sclerosis Ms ,S Multiple Sclerosis ,Clinical Research ,